---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-000364"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2023-01-06T23:59:59+00:00"
generated_at: "2026-06-20T18:49:17.666219+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Athira enters ATM stock offering; reports ~$245.2M cash as of Dec 31, 2022

## Summary
- Entered Sales Agreement with Cantor Fitzgerald & BTIG for at-the-market offering of common stock.
- Agents to receive 3.0% of gross proceeds; Company has no obligation to sell any shares.
- Preliminary cash, equivalents and investments total ~$245.2M as of Dec 31, 2022 (unaudited).
- Shares to be issued under effective shelf registration statement on Form S-3 (File No. 333-261073).
- Prospectus supplement dated Jan 6, 2023 filed with SEC.

## SEC filing metadata
- accession: 0000950170-23-000364
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2023-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/0000950170-23-000364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/atha-20230106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-000364
- JSON: https://secwatch.observer/filing/0000950170-23-000364.json
- Plain text: https://secwatch.observer/filing/0000950170-23-000364.txt

## Key facts
- Material Agreements
  LeonaBio, Inc. entered into Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and BTIG, LLC valued at maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement (effective 2023-01-06).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Cantor Fitzgerald & Co. and BTIG, LLC
  - Value: maximum aggregate dollar amount registered pursuant to the applicable prospectus supplement
  - Effective: 2023-01-06
  source text: On January 6, 2023, Athira Pharma, Inc, a Delaware corporation (the “Company”), entered into a Controlled Equity Offering Sales Agreement SM (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor”) and BTIG, LLC (“BTIG” and together with Cantor, the “Agents” and each, an “Agent”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1620463/000095017023000364/0000950170-23-000364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.